InvestorsHub Logo
Followers 698
Posts 138570
Boards Moderated 3
Alias Born 07/29/2006

Re: Stock Lobster post# 328804

Tuesday, 07/20/2010 8:18:49 AM

Tuesday, July 20, 2010 8:18:49 AM

Post# of 648882
WSJ: Biogen Net More Than Doubles on Higher Sales

JULY 20, 2010, 8:02 A.M. ET

By MATT JARZEMSKY

Biogen Idec Inc.'s earnings more than doubled, with its Tysabri drug again showing strong sales gains.

The company raised its current-year earnings estimate by 15 cents to at least $4.70 a share.

The results come as the maker of multiple-sclerosis treatments faces concerns about the sales growth of Tysabri, which is sold with Elan Corp. The U.S. Food and Drug Administration has maintained the drug's benefits outweigh risks of a rare and serious brain infection linked to it.

Biogen's chief executive departed last month and the chief operating officer plans to do the same at the end of the year.

Biogen reported a second-quarter profit of $294.6 million, or $1.12 a share, up from $144.9 million, or 49 cents a share, a year earlier. Excluding restructuring costs and other items, profit soared to $1.31 from 75 cents. Revenue rose 11% to $1.21 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.12 on $1.13 billion in revenue. Such estimates typically exclude items.

Sales of Tysabri rose 17% as the estimated number of patients world-wide rose 4.8% from the prior quarter. Fellow MS treatment Avonex—the company's biggest seller—posted a 6.3% increase.

Write to Matt Jarzemsky at matthew.jarzemsky@dowjones.com

http://online.wsj.com/article/SB10001424052748703724104575378764010849770.html?mod=rss_whats_news_us_business

_______________________________________________________
If you take anything I say as advice, you're crazier than I am.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.